Rocket Pharmaceuticals, Inc. RCKT
Set alert
2.47 USD +0.03 +1.23%
At close · Nov 2
2.45 -0.02 -0.98%
After hours · Nov 2, 4:00 PM ET
2.39 Day range 2.50
2.17 52-week range 5.45
- YTD
- -29.63%
- 1 year
- -34.48%
- Open
- 2.44
- Prev close
- 2.44
- Mkt cap
- 271.14M
- Vol
- 1.82M
- Avg vol
- 1.82M
- EPS
- -0.17
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.39
- High
- 2.50
- Forward P/E
- -3.35
- Beta
- 1.02
- Short ratio
- 7.72
- Inst. own
- 106.93%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.92
- 200-d avg
- 17.12
- 1y target
- 40.93
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 40.93 +1557.0% upside
Now 2.47
- Target (low)
- 29.00
- Target (mean)
- 40.93
- Target (high)
- 55.00
Ratings (0m) 17 16 buy · 1 hold · 0 sell
- Strong buy4
- Buy12
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 17
- 1 month ago 17
- 2 months ago 18
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.6125 | -0.82 – -0.50004 | -0.66 | +7.2% | 888.89K | 0.0% | 12 |
| Next quarter | -0.61976 | -0.87 – -0.49717 | -0.74 | +16.3% | 1.11M | 0.0% | 12 |
| Current year | -2.23 | -3.37 – -0.30 | -2.73 | +18.4% | 42.90M | 0.0% | 16 |
| Next year | -1.62 | -2.51 – -0.04 | -2.23 | +27.3% | 96.32M | +124.5% | 16 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 3, 2025 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Mar 3, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Mar 3, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Feb 28, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Feb 28, 2025 | Needham | Maintained | Buy | Buy |
| Dec 18, 2024 | Jefferies | Initiated | — | Buy |
| Nov 19, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 19, 2024 | Leerink Partners | Maintained | Outperform | Outperform |
| Nov 19, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Nov 19, 2024 | Needham | Reiterated | Buy | Buy |
| Nov 18, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 11, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 8, 2024 | Needham | Reiterated | Buy | Buy |
| Oct 16, 2024 | Scotiabank | Initiated | — | Sector Outperform |
| Sep 30, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 17, 2024 | Needham | Reiterated | Buy | Buy |
| Aug 6, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 6, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 6, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Aug 6, 2024 | Needham | Reiterated | Buy | Buy |
| Jul 3, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 28, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Jun 28, 2024 | Needham | Maintained | Buy | Buy |
| May 7, 2024 | Needham | Reiterated | Buy | Buy |
| Apr 10, 2024 | Needham | Reiterated | Buy | Buy |
| Apr 2, 2024 | Goldman Sachs | Initiated | — | Neutral |
| Mar 1, 2024 | UBS | Maintained | Buy | Buy |
| Feb 27, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Feb 27, 2024 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Feb 13, 2024 | Needham | Reiterated | Buy | Buy |